Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib vs sunitinib in imatinib-resistant gastrointestinal stromal tumor
2011-001790-41Phase 3Active
- Sponsor
- AB Science
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of masitinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by AB Science. Primary endpoint: Overall Progression Free Survival. Started Jun 2011; status: active.
02
Drugs
masitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2011-001790-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001790-41.